Stifel maintains Buy rating on Pulmonx, $4 price target
Stifel kept a Buy rating on Pulmonx with a $4 price target, suggesting 102% upside from the last close. The company reported 6.8% YoY U.S. sales growth and 18% reduced operating expenses, with a 76.2% gross margin.
How this was made

The 30-second read
Why it matters
The rating and target could trigger short-term buying pressure.
Market read
Analyst coverage may move the stock higher in the near term.
What to watch
Potential regulatory delays or competition could temper upside.
Background
Stifel's analyst note highlights revenue growth, margin expansion, and cost reductions for Pulmonx.
Market effects
May lift sentiment in the pulmonary disease biotech niche.
Limited to US biotech investors.
Minor, confined to Pulmonx shareholders.
Counterpoint
Some investors may view the target as overly optimistic given limited commercial rollout.
Key entities
- CompanyPulmonx
Biotech firm developing treatments for severe emphysema.
- AnalystStifel
Investment bank providing the rating and price target.
